Connect with us

Corona News

Emergency Use: China’s Sinopharm Vaccine Gets WHO Approval

Published

on

In a latest development, the World Health Organisation approved Sinopharm for emergency use against COVID-19. This became the first vaccine from China to get approval from WHO. Sinopharm vaccine has 79% efficacy.

The WHO has already given emergency use listing to the vaccines being made by Pfizer-BioNTech, Moderna, Johnson and Johnson, and the AstraZeneca jab. These vaccines are produced at different places in India and South Korea.

WHO chief Tedros Adhanom Ghebreyesus in a press conference said that, “WHO gave emergency use listing to Sinopharm Beijing’s COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality.”

He further added that, “The Strategic Advisory Group of Experts on Immunisation, or SAGE, has also reviewed the available data, and recommends the vaccine for adults 18 years and older, with a two-dose schedule.”

According to the reports, before the WHO approval, the Sinopharm vaccine was already being widely used. It is said that 65 million doses have been administered. Not only in China, this vaccine was also used in the UAE, Pakistan and Hungary.

WHO is yet to come to a decision on China’s Sinovac vaccine. One of the main advantage of Chinese vaccines’ is that they can be stored in a standard refrigerator at 2 to 8 degrees Celsius just like that of AstraZeneca vaccine.

Corona News

People With HIV, AIDS Less Exposed To Coronavirus

Published

on

Researchers at Delhi’s All India Institute of Medical Sciences (AIIMS) discovered that seroprevalence, or the existence of antibodies, was less among those living with HIV and AIDS. This suggests that patients with HIV or AIDS have been exposed to Covid-19 at a lower rate than the general population.

The study, which took place between September and November 2020, included 164 HIV or AIDS patients with an average age of 41 years. Only 23 out of 164 patients (14%) were discovered to have antibodies, according to the study.

“A total of 164 patients were recruited in the study with a mean age (+SD) of 41.2 (+15.4) years and 55 per cent male population. Positive serology against SARS CoV-2 was detected in 14 per cent of patients (95 per cent C 9.1-20.3 per cent). The seroprevalence of Covid-19 disease in people living with HIV and AIDS was found to be lower than the general population,” says the study.

According to the study, most seropositive patients had minor or no symptoms with Covid-19.

However, the actual explanation for this reduced seroprevalence remains a mystery. According to the study, low seroprevalence is attributed to patients remaining indoors and avoiding social contact for fear of contracting the disease. They may not have contracted the disease as a result of this.

The study reads, “Another reason for this could be that these patients might not have generated antibodies against Covid-19 or may not have sustained it after getting infected.”

According to the study, persons who are infected wiht the virus should not take it lightly and should continue to observe social distancing rules.

Continue Reading

Corona News

Covishield Produces Strong Immune Response With 11 Month Gap?

Published

on

covishield AstraZeneca vaccine

According to a research in the UK, the AstraZeneca Covid-19 vaccine produces a better immune response with a longer dose gap of up to 45 weeks. The third shot can enhance antibody levels even more. The study shows that the level of antibodies will be high at least one year after a single dose of Covishield in India where the gap between the two doses has been set at 12 to 16 weeks.

An extended gap of up to 45 weeks, or nearly 11 months, between the first and second doses of the AstraZeneca vaccine resulted in an 18-fold increase in antibody response measured 28 days after the second dosage, according to the study’s authors.

Volunteers aged 18 to 55 years old who were enrolled in the studies and had already received either a single dose or two doses of AstraZeneca vaccine were included in the study, which was published on The Lancet’s pre-print website on Monday.

Professor Andrew J Pollard, chief investigator and director of the Oxford Vaccine Group at the University of Oxford said that, “This should come as reassuring news to countries with lower supplies of the vaccine, who may be concerned about delays in providing second doses to their populations. There is an excellent response to a second dose, even after a 10-month delay from the first.”

According to the study, “The third dose also resulted in higher neutralising activity against the Alpha, Beta, and Delta variants.”

Continue Reading

Corona News

Covid Vaccine Should Be Given To Pregnant Women

Published

on

The dangerous coronavirus has created a lot of problem to the people. The second wave of COVID-19 is more dangerous than the first one. The government of India is taking all the measures to control the spread of coronavirus. People are getting vaccinated. Three vaccines – Covaxin, Covishield and Sputnik V – have got approval for use in India. Many institutes are working hard to come up with vaccines that work against coronavirus.

Now, the news is that, Indian Council for Medical Research (ICMR) Director-General Dr Balram Bhargava said that coronavirus vaccine should be given to pregnant women as it is useful for them.
He said that, “The Ministry of Health has given the guideline that vaccine can be given to pregnant women. Vaccination is useful in pregnant women, and it should be given.”

While addressing a press conference on the Covid-19 situation in the country, he said that only one country is giving coronavirus vaccine to children. He further added that a study on children in the age group of 2 to 18 has been conducted, and results are likely to come in by September. The government will soon release guidelines for vaccination of pregnant women against Covid-19. Currently, only lactating women in India have been recommended to take the Covid-19 vaccine.

According to the reports, the pregnant and postpartum women were more severely affected during the second COVID-19 wave in India than the first.

Continue Reading
Advertisement

Poll

Lockdown Helpful in Reducing COVID Cases..?

Trending